CFDE Data Portal | Search TOX-DT

	Label	Description
	TOX-DT Gene (Entity type)	ENSG00000167912 - TOX divergent transcript
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 etoposide leukocyte 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

TOX-DT

ENSG00000167912 - TOX divergent transcript

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE120612 etoposide leukocyte 6 v 1 human up

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.